Aegis Capital initiated coverage of IntelGenx (OTCQX:IGXT) with a “buy” rating and $3 price target. The stock closed at 88 cents on Jan. 26.Read More
Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.
Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served as CFO for Viacell, a stem cell company purchased by PerkinElmer.Read More
Atossa Genetics (NASDAQ:ATOS) has priced a public offering of 1,150,000 common shares at a price of $2.50 a share for gross proceeds of about $2,875,000.
Atossa Genetics also granted underwriters a 45-day option to purchase up to an additional 172,500 shares to cover over-allotments. The offering is expected to close on Sept. 6.Read More